Interruption of the intratumor CD8+ T cell:Treg crosstalk improves the efficacy of PD-1 immunotherapy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Interruption of the intratumor CD8+ T cell:Treg crosstalk improves the efficacy of PD-1 immunotherapy

Published:2024-06 Issue:6 Volume:42 Page:1051-1066.e7
ISSN:1535-6108
Container-title:Cancer Cell
language:en
Short-container-title:Cancer Cell

Author:

Geels Shannon N.,Moshensky Alexander,Sousa Rachel S.,Murat Claire,Bustos Matias A.,Walker Benjamin L.,Singh Rima,Harbour Stacey N.,Gutierrez Giselle,Hwang Michael,Mempel Thorsten R.,Weaver Casey T.,Nie Qing,Hoon Dave S.B.,Ganesan Anand K.,Othy Shivashankar,Marangoni Francesco^ORCID

Publisher

Elsevier BV

Reference83 articles.

1. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer;Borghaei;N. Engl. J. Med.,2015

2. Nivolumab for recurrent squamous-cell carcinoma of the head and neck;Ferris;N. Engl. J. Med.,2016

3. PD-1 blockade with pembrolizumab in advanced merkel-cell carcinoma;Nghiem;N. Engl. J. Med.,2016

4. PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma;Migden;N. Engl. J. Med.,2018

5. Nivolumab plus Ipilimumab versus Sunitinib in advanced renal-cell carcinoma;Motzer;N. Engl. J. Med.,2018

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cell Identity and Spatial Distribution of PD‐1/PD‐L1 Blockade Responders;Advanced Science;2024-09-09

2. Breaking up the CD8+ T cell: Treg pas de deux;Cancer Cell;2024-06

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP